公司近期动态 - 公司副总裁兼外部制造负责人John Wiggins将于美东时间6月3日周三下午12:10在William Blair第46届年度成长股会议上参与炉边谈话[1] 公司信息获取渠道 - 相关演讲的网络直播可通过公司官网投资者关系栏目访问[2] - 网络直播的回放将在公司官网上提供至少30天[2] 公司背景 - 公司是领先的专注于放射性药物的企业，致力于通过变革性科学帮助临床医生发现、对抗和追踪疾病以改善患者预后[3] - 公司总部位于马萨诸塞州，在美国新泽西、加拿大、德国、瑞典、瑞士和英国设有办事处[3] - 公司提供放射性药物解决方案已有70年历史[3]

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com. Contacts: Mark Kinarney Vice President, Investor Relations 978-671-8842 ir@lantheus.com ...

CHF 26.4 million (EUR 28.4 million) extension, led by existing investors, accelerates clinical development of NU101 and NU201 radiotheranostic programs in metastatic castration resistant prostate cancer and metastatic breast cancer Basel, Switzerland / Munich, Germany, May 27, 2026 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company, today announced the closing of an oversubscribed CHF 26 million (EUR 28.4 million) Series B extension, bringing the Series B total raised to CHF 105 million (approxima ...